Journal ArticleOPEN ACCESS

Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups

Blood Cancer Journal (2016) 6(1)
DOI: 10.1038/bcj.2015.115
5Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Gagez, A. L., Tuaillon, E., Cezar, R., Dartigeas, C., Mahé, B., Letestu, R., … Cartron, G. (2016). Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups. Blood Cancer Journal, 6(1). https://doi.org/10.1038/bcj.2015.115

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free